Copper (64Cu) oxodotreotide

What Is Copper (64Cu) oxodotreotide?[edit | edit source]

Copper (64Cu) oxodotreotide (Detectnet) is a radioactive diagnostic agent indicated for use with positron emission tomography (PET).

Detectnet is a drug for detection of the specific type of tumors called somatostatin receptor positive neuroendocrine tumors (NETs) in adults.
NETs are rare tumors that develop in certain hormone-producing cells of the body’s neuroendocrine system.

Copper Cu 64 dotatate binds to somatostatin receptors with highest affinity for subtype 2 receptors (SSTR2).
It binds to cells that express somatostatin receptors including malignant neuroendocrine cells, which overexpress SSTR2 receptors.
Copper Cu 64 is a positron (β+) emitting radionuclide with an emission yield that allows positron emission tomography (PET) imaging.

Handle Detectnet with appropriate safety measures to minimize radiation exposure.
Use waterproof gloves, effective radiation shielding and appropriate safety measures when preparing and handling Detectnet.
In adults, the recommended amount of radioactivity to be administered for PET imaging is 148 MBq (4 mCi) administered as an intravenous injection over a period of approximately 1 minute.
Begin acquiring images 45 to 90 minutes after drug administration.

Administration

Use Detectnet within 2 hours after calibration time.
Use aseptic technique and radiation shielding when withdrawing and administering Detectnet.
Inspect Detectnet visually for particulate matter and discoloration before administration. Do not use the drug if the solution contains particulate matter or is discolored.
Calculate the necessary volume to administer based on measured activity, volume, calibration time, and date.
Use a dose calibrator to measure the patient dose immediately prior to administration of Detectnet.
After injection of Detectnet, administer an intravenous flush of 0.9% sodium chloride injection, USP.
Dispose of any unused drug in a safe manner in compliance with applicable regulations.

This medicine is available in fallowing doasage form:

As Injection: 148 MBq (4 mCi) (37 MBq (1 mCi) per 1 mL) of copper Cu 64 dotatate in a single-dose vial.

This medicine is available in fallowing brand namesː

Common possible side effects of this medicine include:

Ensure safe handling and preparation procedures to protect patients and health care workers from unintentional radiation exposure.
Advise patients to hydrate before and after administration and to void frequently after administration.
A negative scan after the administration of Detectnet in patients who do not have a history of NET disease does not rule out disease.

In the event of a radiation overdose, the absorbed dose to the patient should be reduced where possible by increasing the elimination of the radionuclide from the body by reinforced hydration and frequent bladder voiding.
A diuretic might also be considered.
If possible, estimation of the radioactive dose given to the patient should be performed.

There are no data on Detectnet use in pregnant women to evaluate for a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes.
All radiopharmaceuticals, including Detectnet have the potential to cause fetal harm depending on the fetal stage of development and the magnitude of the radiation dose.
Advise a pregnant woman of the potential risks of fetal exposure to radiation from administration of Detectnet.

The safety and effectiveness of Detectnet have not been established in pediatric patients.

Store Detectnet in an upright position within the lead shielding to protect handlers from exposure to radiation.
Store Detectnet at controlled room temperature 20°C to 25°C (68°F to 77°F). Do not use and discard Detectnet 2 hours after the calibration date and time.

This pharmacology-related article is a stub. You can help WikiMD by expanding it.

Copper (64Cu) oxodotreotide Resources
Need Help Finding a Doctor? Need help finding a doctor or specialist anywhere in the world? Explore our world directory. WikiMD's DocFinder can assist you in locating millions of physicians.	Medical Knowledge Access the latest research - Most recent articles Ongoing trials.